Eli Lilly And Co (LLY) Shares Sold by State Board of Administration of Florida Retirement System

State Board of Administration of Florida Retirement System lowered its stake in Eli Lilly And Co (NYSE:LLY) by 0.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,338,457 shares of the company’s stock after selling 11,329 shares during the quarter. State Board of Administration of Florida Retirement System owned about 0.12% of Eli Lilly And Co worth $114,211,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of LLY. Integrated Wealth Concepts LLC acquired a new stake in Eli Lilly And Co in the second quarter worth about $103,000. Legacy Advisors LLC raised its position in Eli Lilly And Co by 118.0% in the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock worth $116,000 after acquiring an additional 733 shares in the last quarter. Financial Management Professionals Inc. bought a new stake in Eli Lilly And Co in the second quarter worth about $128,000. Stelac Advisory Services LLC bought a new stake in Eli Lilly And Co in the first quarter worth about $134,000. Finally, Kiley Juergens Wealth Management LLC bought a new stake in Eli Lilly And Co in the second quarter worth about $140,000. 76.62% of the stock is owned by institutional investors and hedge funds.

Eli Lilly And Co opened at $102.25 on Friday, according to MarketBeat.com. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40. The stock has a market cap of $109.75 billion, a price-to-earnings ratio of 23.89, a P/E/G ratio of 1.70 and a beta of 0.27. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $103.81.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.20. The firm had revenue of $6.36 billion for the quarter, compared to the consensus estimate of $6.05 billion. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.11 EPS. sell-side analysts expect that Eli Lilly And Co will post 5.47 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 10th. Shareholders of record on Wednesday, August 15th will be issued a dividend of $0.5625 per share. The ex-dividend date is Tuesday, August 14th. This represents a $2.25 annualized dividend and a yield of 2.20%. Eli Lilly And Co’s payout ratio is presently 52.57%.

LLY has been the topic of several research reports. HC Wainwright reiterated a “buy” rating on shares of Eli Lilly And Co in a research report on Wednesday, April 18th. Credit Suisse Group set a $80.00 price target on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Sunday, April 22nd. Goldman Sachs Group set a $100.00 price target on shares of Eli Lilly And Co and gave the stock a “neutral” rating in a research report on Wednesday, July 25th. Zacks Investment Research cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Wednesday, May 23rd. Finally, ValuEngine cut shares of Eli Lilly And Co from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company. Eli Lilly And Co currently has an average rating of “Hold” and a consensus price target of $100.13.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $98.74, for a total transaction of $20,241,700.00. Following the sale, the insider now owns 121,121,794 shares in the company, valued at approximately $11,959,565,939.56. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Christi Shaw sold 8,426 shares of the business’s stock in a transaction dated Tuesday, May 29th. The stock was sold at an average price of $82.10, for a total value of $691,774.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,575,728 shares of company stock worth $144,624,164. Corporate insiders own 0.11% of the company’s stock.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: Diversification Important in Investing

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply